HP's High Yield Masks Looming Cost and Execution Risks

What happened

HP reported Q1'FY26 revenue growth of 6.9%, with personal systems gains offsetting printing declines, as highlighted in a Seeking Alpha article that touts a double-digit yield opportunity. The article recommends a Strong Buy based on robust cash flow and a combined dividend and buyback yield near 13.7%, framing hardware weakness as a chance for income investors. However, DeepValue's master report, grounded in SEC filings, maintains a WAIT rating due to significant risks from memory inflation, tariffs, and structural declines in print supplies. Key concerns center on HP's ability to pass through higher costs without triggering demand destruction, with evidence needed in the next 6-9 months on pricing actions and cost savings. Despite the attractive yield, the stock's cheap valuation reflects market skepticism about earnings durability amid these headwinds.

Implication

The high yield offered by HP is enticing but depends on sustained cash flow, which is threatened by memory and tariff costs that have already compressed margins. Management's restructuring plan targeting $300M savings in FY26 must deliver to support earnings, but past quarters show profitability erosion despite volume growth, indicating execution challenges. External factors like DRAM pricing trends must be monitored, as continued tightness could exacerbate the margin squeeze expected in 2H FY26, limiting upside. The interim CEO transition adds an extra layer of execution risk, requiring investors to verify that guidance holds under new leadership. Therefore, while the stock screens cheap on multiples, a cautious approach is warranted until clearer signs of earnings stability and successful cost pass-through emerge.

Thesis delta

The Seeking Alpha article emphasizes yield and cash flow as reasons to buy, but it overlooks the core execution risks detailed in the DeepValue report, such as memory cost pass-through and savings delivery. No new information alters the need for observable proof in the next 6-9 months, so the thesis remains that investors should wait for evidence before considering an entry, reinforcing the WAIT rating.